Ryan Sullivan
Long/short equity, biotech, growth, long-term horizon

BIND Therapeutics Is Worth $18/Share

Article Overview

BIND Therapeutics (NASDAQ:BIND) is a developmental-stage drug company that went public on September 20th, 2013, at a price of $15/share. The stock currently trades at $13.90/share, with a market capitalization of $237M.

Here, I provide an overview of the company's long-term prospects, as well as a valuation of the shares based on a probabilistic discounted cash flow model.

Management and Insider Ownership

A number of important insiders are heavily invested in BIND, including its two founders, Omid Farokhzad (2.3% of company) and Robert Langer, an Institute Professor at MIT and founder of a number of other companies (5.3% of company). David H. Koch also owns 6% of the company, which was upped to 8.9% after the...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details